Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Sim HW, Wachsmuth L, Barnes EH, Yip S, Koh ES, Hall M, Jennens R, Ashley DM, Verhaak RG, Heimberger AB, Rosenthal MA, Hovey EJ, Ellingson BM, Tognela A, Gan HK, Wheeler H, Back M, McDonald KL, Long A, Cuff K, Begbie S, Gedye C, Mislang A, Le H, Johnson MO, Kong BY, Simes JR, Lwin Z, Khasraw M. Sim HW, et al. Among authors: kong by. Neurooncol Adv. 2023 Sep 22;5(1):vdad124. doi: 10.1093/noajnl/vdad124. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37841696 Free PMC article.
Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers.
Halkett GKB, Breen LJ, Berg M, Sampson R, Sim HW, Gan HK, Kong BY, Nowak AK, Day BW, Harrup R, James M, Saran F, Mcfarlane B, Tse C, Koh ES. Halkett GKB, et al. Among authors: kong by. Curr Oncol. 2022 Dec 17;29(12):9928-9955. doi: 10.3390/curroncol29120781. Curr Oncol. 2022. PMID: 36547195 Free PMC article.
Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study.
Agar MR, Nowak AK, Hovey EJ, Barnes EH, Simes J, Vardy JL, Wheeler HR, Kong BY, Leonard R, Hall M, Tim E, Spyridopoulos D, Sim HW, Lwin Z, Dowling A, Harrup R, Jennens R, Kichenadasse G, Dunlop T, Gzell C, Koh ES. Agar MR, et al. Among authors: kong by. BMJ Support Palliat Care. 2023 Sep;13(3):354-362. doi: 10.1136/spcare-2022-004119. Epub 2023 Feb 17. BMJ Support Palliat Care. 2023. PMID: 36807048 Clinical Trial.
BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience.
Trinder SM, McKay C, Power P, Topp M, Chan B, Valvi S, McCowage G, Govender D, Kirby M, Ziegler DS, Manoharan N, Hassall T, Kellie S, Heath J, Alvaro F, Wood P, Laughton S, Tsui K, Dodgshun A, Eisenstat DD, Endersby R, Luen SJ, Koh ES, Sim HW, Kong B, Gottardo NG, Whittle JR, Khuong-Quang DA, Hansford JR. Trinder SM, et al. Front Oncol. 2023 Apr 14;13:1154246. doi: 10.3389/fonc.2023.1154246. eCollection 2023. Front Oncol. 2023. PMID: 37124503 Free PMC article. Review.
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.
Kong BY, Sim HW, Nowak AK, Yip S, Barnes EH, Day BW, Buckland ME, Verhaak R, Johns T, Robinson C, Thomas MA, Giardina T, Lwin Z, Scott AM, Parkinson J, Jeffree R, Lourenco RA, Hovey EJ, Cher LM, Kichendasse G, Khasraw M, Hall M, Tu E, Amanuel B, Koh ES, Gan HK. Kong BY, et al. BMJ Open. 2021 Dec 30;11(12):e054075. doi: 10.1136/bmjopen-2021-054075. BMJ Open. 2021. PMID: 37185327 Free PMC article.
The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Oh B, Boyle F, Pavlakis N, Clarke S, Eade T, Hruby G, Lamoury G, Carroll S, Morgia M, Kneebone A, Stevens M, Liu W, Corless B, Molloy M, Kong B, Libermann T, Rosenthal D, Back M. Oh B, et al. Cancers (Basel). 2021 Sep 27;13(19):4824. doi: 10.3390/cancers13194824. Cancers (Basel). 2021. PMID: 34638308 Free PMC article. Review.
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study.
Brown LJ, Khou V, Brown C, Alexander M, Jayamanne D, Wei J, Gray L, Chan WY, Smith S, Harden S, Mersiades A, Warburton L, Itchins M, Lee JH, Pavlakis N, Clarke SJ, Boyer M, Nagrial A, Hau E, Pires da Silva I, Kao S, Kong BY. Brown LJ, et al. Among authors: kong by. Front Oncol. 2024 Feb 7;14:1305720. doi: 10.3389/fonc.2024.1305720. eCollection 2024. Front Oncol. 2024. PMID: 38406805 Free PMC article.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Long GV, et al. Among authors: kong by. Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17. Lancet Oncol. 2017. PMID: 28729151 Free article. Clinical Trial.
53 results